Pharmaceutical Research

, Volume 24, Issue 10, pp 1919–1926

A Unique Iontophoretic Patch for Optimal Transdermal Delivery of Sumatriptan

  • Steven J. Siegel
  • Carol O’Neill
  • Louise M. Dubé
  • Peter Kaldeway
  • Russell Morris
  • David Jackson
  • Terri Sebree
Research Paper

DOI: 10.1007/s11095-007-9317-1

Cite this article as:
Siegel, S.J., O’Neill, C., Dubé, L.M. et al. Pharm Res (2007) 24: 1919. doi:10.1007/s11095-007-9317-1

Abstract

Purpose

Migraines affect approximately 10% of the adult population worldwide. The purpose of this study was to assess the pharmacokinetic and safety profile of a novel iontophoretic sumatriptan delivery system, NP101, which uses an electrical current to propel sumatriptan across intact skin and into underlying tissue. Four unique prototype iontophoretic sumatriptan patch conditions were compared to a 6 mg subcutaneous injection and an oral 50 mg tablet of sumatriptan succinate.

Materials and Methods

This was a randomized, single-center, single-dose, six-period Phase I study.

Results

Patches were well tolerated with fewer adverse events than the subcutaneous injection. Adverse events that were more prevalent for NP101 than other formulations included localized sensations and reactions at the patch site. A linear relationship was observed between total applied current and sumatriptan delivery. Patches delivering 6 and 12 mA per h yielded favorable sumatriptan systemic profiles, delivering drug at a rate that maintained plasma levels above the target level (≥10 ng/ml) for greater than 7 h.

Conclusions

This study met the initial objective to define the dose–current relationship in humans as well as delimiting specific current and current density targets for a well tolerated patch design that can deliver therapeutic drug levels for longer periods than currently possible.

Key words

clinical trialiontophoresismigrainephase Isumatriptan

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Steven J. Siegel
    • 1
  • Carol O’Neill
    • 2
  • Louise M. Dubé
    • 2
  • Peter Kaldeway
    • 3
  • Russell Morris
    • 4
  • David Jackson
    • 2
  • Terri Sebree
    • 2
  1. 1.Division of NeuropsychiatryUniversity of Pennsylvania, Translational Research LaboratoriesPhiladelphiaUSA
  2. 2.NuPathe Inc.ConshohockenUSA
  3. 3.Kendle International Clinical Pharmacology UnitUtrechtThe Netherlands
  4. 4.Travanti Pharma Inc.Mendota HeightsUSA